In Vitro and in Vivo Effects of Nitrofurantoin on Experimental Toxoplasmosis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Toxoplasma gondii is an important opportunistic pathogen that causes toxoplasmosis, which has very few therapeutic treatment options. The most effective therapy is a combination of pyrimethamine and sulfadiazine; however, their utility is limited because of drug toxicity and serious side effects. For these reasons, new drugs with lower toxicity are urgently needed. In this study, the compound, (Z)-1-[(5-nitrofuran-2-yl)methyleneamino]-imidazolidine-2,4-dione (nitrofurantoin), showed anti-T. gondii effects in vitro and in vivo. In HeLa cells, the selectivity of nitrofurantoin was 2.3, which was greater than that of pyrimethamine (0.9). In T. gondii-infected female ICR mice, the inhibition rate of T. gondii growth in the peritoneal cavity was 44.7% compared to the negative control group after 4-day treatment with 100 mg/kg of nitrofurantoin. In addition, hematology indicators showed that T. gondii infection-induced serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, biochemical parameters involved in liver injury, were reduced by nitrofurantoin significantly. Moreover, nitrofurantoin exerted significant effects on the index of antioxidant status, i.e., malondialdehyde (MDA) and glutathione (GSH). The nitrofurantoin-treated group inhibited the T. gondii-induced MDA levels while alleviating the decrease in GSH levels. Thus, nitrofurantoin is a potential anti-T. gondii candidate for clinical application.
Abstract
Toxoplasma gondii is an important opportunistic pathogen that causes toxoplasmosis, which has very few therapeutic treatment options. The most effective therapy is a combination of pyrimethamine and sulfadiazine; however, their utility is limited because of drug toxicity and serious side effects. For these reasons, new drugs with lower toxicity are urgently needed. In this study, the compound, (Z)-1-[(5-nitrofuran-2-yl)methyleneamino]-imidazolidine-2,4-dione (nitrofurantoin), showed anti-T. gondii effects in vitro and in vivo. In HeLa cells, the selectivity of nitrofurantoin was 2.3, which was greater than that of pyrimethamine (0.9). In T. gondii-infected female ICR mice, the inhibition rate of T. gondii growth in the peritoneal cavity was 44.7% compared to the negative control group after 4-day treatment with 100 mg/kg of nitrofurantoin. In addition, hematology indicators showed that T. gondii infection-induced serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, biochemical parameters involved in liver injury, were reduced by nitrofurantoin significantly. Moreover, nitrofurantoin exerted significant effects on the index of antioxidant status, i.e., malondialdehyde (MDA) and glutathione (GSH). The nitrofurantoin-treated group inhibited the T. gondii-induced MDA levels while alleviating the decrease in GSH levels. Thus, nitrofurantoin is a potential anti-T. gondii candidate for clinical application.
참고문헌 (30)
- Tenter AM, "Toxoplasma gondii in animals used for human consumption", Mem Inst Oswaldo Cruz, 104, pp.364~369 (2009)
- Sabin AB, "Chorioretinopathy associated with other evidence of cerebral damage in childhood; a syndrome of unknown etiology separable from congenital toxoplasmosis", J Pediatr, 35, pp.296~309 (1949)
- Dubey JP, "Toxoplasma gondii, Neospora caninum, Sarcocystis neurona, and Sarcocystis canis-like infections in marine mammals", Vet Parasitol, 116, pp.275~296 (2003)
- Sabin AB, "Therapeutic effectiveness of certain sulfonamide on infection by an intracellular protozoon(Toxoplasma)", Proc Soc Exp Biol Med, 51, pp.19~23 (1942)
- Eyles DE, "The effect of metabolites on the antitoxoplasmic action of pyrimethamine and sulfadiazine", Am J Trop Med Hyg, 9, pp.277~283 (1960)
- Garin JP, "Le traitement de la toxoplasmose experimentale de la souris par la spiramycine", Presse Medicale, 66, pp.957~958 (1958)
- Desmonts G, "Toxoplasmosis in pregnancy and its transmission to the fetus", Bull N Y Acad Med, 50, pp.146~159 (1974)
- Dubey JP, "Transplacental toxoplasmosis in naturally-infected white-tailed deer: isolation and genetic characterisation of Toxoplasma gondii from foetuses of different gestational ages", Int J Parasitol, 38, pp.1057~1063 (2008)
- Araujo FG, "Effect of clindamycin on acute and chronic toxoplasmosis in mice", Antimicrob Agents Chemother, 5, pp.647~651 (1974)
- Dannemann B, "A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine", Ann Intern Med, 116, pp.33~43 (1992)
- Georgiev VS, "Management of toxoplasmosis", Drugs, 48, pp.179~188 (1994)
- Luft BJ, "Toxoplasmic encephalitis in AIDS", Clin Infect Dis, 15, pp.211~222 (1992)
- Jin C, "Toxoplasma gondii: a simple high-throughput assay for drug screening in vitro", Exp Parasitol, 121, pp.132~136 (2009)
- Ohkawa H, "Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction", Anal Biochem, 95, pp.351~358 (1979)
- Griffith OW, "Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine", Anal Biochem, 106, pp.207~212 (1980)
- Reitman S, "A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases", Am J Clin Pathol, 28, pp.56~63 (1957)
- Jiang JH, "Anti-toxoplasmosis effects of oleuropein isolated from Fraxinus rhychophylla", Biol Pharm Bull, 31, pp.2273~2276 (2008)
- Wessels FL, "Synthesis and antidepressant activity of 5-(4-dimethylaminobenzyl)imidazolidine-2,4-dione", J Pharm Sci, 69, pp.1102~1104 (1980)
- Zejc A, "Synthesis and pharmacological properties of diphenylimidazolidine acetic and propionic acids derivatives", Pol J Pharmacol Pharm, 41, pp.483~493 (1989)
- Kiec-Kononowicz K, "Synthesis and antiarrhythmic properties of basic amide derivatives of imidazolidine-2,4-dione and pyrrolidine-2,5-dione II", Farmaco, 50, pp.355~360 (1995)
- Niwata S, "Substituted 3-(phenylsulfonyl)-1-phenylimidazolidine-2,4-dione derivatives as novel nonpeptide inhibitors of human heart chymase", J Med Chem, 40, pp.2156~2163 (1997)
- Muccioli GG, "Substituted 2-thioxoimidazolidin-4-ones and imidazolidine-2,4-diones as fatty acid amide hydrolase inhibitors templates", J Med Chem, 49, pp.417~425 (2006)
- Mukherjee A, "Evaluation of fluoren-NU as a novel antitumor agent", Oncol Res, 17, pp.387~396 (2009)
- Reddy YT, "Novel substituted (Z)-5-((N-benzyl-1H-indol-3-yl)methylene)imidazolidine-2,4-diones and 5-((N-benzyl-1H-indol-3-yl)methylene)pyrimidine-2,4,6(1H,3H,5H)-triones as potent radio-sensitizing agents", Bioorg Med Chem Lett, 20, pp.600~602 (2010)
- Derouin F, "Anti-Toxoplasma effects of dapsone alone and combined with pyrimethamine", Antimicrob Agents Chemother, 35, pp.252~255 (1991)
- Piketty C, "In vivo assessment of antimicrobial agents against Toxoplasma gondii by quantification of parasites in the blood, lungs, and brain of infected mice", Antimicrob Agents Chemother, 34, pp.1467~1472 (1990)
- Roca B, "Toxoplasmosis and hepatitis", Med Clin, 99, pp.595~596 (1992)
- Yarim GF, "Serum protein alterations in dogs naturally infected with Toxoplasma gondii", Parasitol Res, 101, pp.1197~1202 (2007)
- Ulku Karaman, "Malondialdehyde, Glutathione, and Nitric Oxide Levels in Toxoplasma gondii Seropositive Patients", The Korean Journal of Parasitology, 46(4), pp.293~295 (2008), 대한기생충학ㆍ열대의학회
- Choi HJ, "6-trifluoromethyl-2-thiouracil possesses anti-Toxoplasma gondii effect in vitro and in vivo with low hepatotoxicity", Exp Parasitol, 143, pp.24~29 (2014)